CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis[1].
Molecular Weight:
(145.85 kDa)
Purity:
98.18
Target:
Interleukin Related
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
